LY3015014

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2015
0120152015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
AIMS The objective of this study was to evaluate the efficacy, safety, and tolerability of LY3015014 (LY), a neutralizing… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2016
2016
LY3015014 is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that binds to the catalytic domain of PCSK9 and reduce low… (More)
  • figure 1
  • table I
  • table II
  • figure 2
  • table III
Is this relevant?
2016
2016
Few interventions in atherosclerosis prevention have been as highly anticipated by the clinical community as the advent of… (More)
  • figure 1
Is this relevant?
2016
2016
and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489–1499. 3. Sabatine MS, Giugliano… (More)
Is this relevant?
2016
2016
Elevated levels of LDL-cholesterol are determined mainly genetically and are the most important risk factor for atherosclerosis… (More)
  • figure 1
  • figure 2
Is this relevant?
2015
2015
Lilly PCSK9 antibody LY3015014 (LY) is a monoclonal antibody (mAb) that neutralizes proprotein convertase subtilisin-kexin type 9… (More)
Is this relevant?